An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
NCT06883552
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer (NSCLC)
Interventions
DRUG:
Tislelizumab Injection
Sponsor
Sichuan University